samedan logo
 
 
 
spacer
home > ebr > spring 2004 > preparing for the due diligence process - plan your way to success
PUBLICATIONS
European Biopharmaceutical Review

Preparing for the Due Diligence Process - Plan your Way to Success

Anyone who has been through a due diligence process will remember it as a painful, time-consuming and frustrating process, but something that has to be endured to get the transaction done. The secret to managing the process is to be organised and plan the process properly. As the target, you must be clear about where the perceived value in the business will be and what will be asked of you. And as the acquirer, you will need to be clear about the business rationale for the transaction and what the key issues for your business are. Verification in the listing process is probably the most exhaustive due diligence process. Therefore, an understanding of what is involved, why it is necessary and the issues that need to be anticipated and planned for can avoid problems and save time later. In our experience, deals run more smoothly and the costs are significantly reduced when the process is properly planned and all the information is readily available. Moreover, a potential purchaser of, or a venture capitalist looking to invest in, a target that has a well-organised and efficient due diligence process, will be left with a strong impression of an effective and able management team, and is less likely to find surprises, ensuring that a company gets maximum value. For companies in the life sciences area, their main asset is likely to be intellectual property. As a consequence, it is likely that any due diligence will focus on assessing the value of their intellectual property, how it is being exploited and how robust their rights are from infringement by third parties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By John Wilkinson and Nicola Maguire, Partners in the Life Sciences Group at Bird & Bird
John Wilkinson is Joint Head of Bird & Bird's Life Sciences group. John has a degree in Chemistry from Imperial College and began his career as a Chemist with Laporte Industries and ICI Pharmaceuticals (now AstraZeneca). After completing his training and qualification as a Solicitor, he specialised in commercial intellectual property. After nine months' legal secondment with a global pharma company, John joined CRCT, the technology transfer arm of the Cancer Research Campaign, as Legal Counsel and Company Secretary. John is a Member of the Intellectual Property Advisory Committee of the Bioindustry Association and the Legal and Regulatory Editor of the Journal of Commercial Biotechnology.


Nicola Maguire is a partner in the Life Sciences group specialising in corporate law with particular experience of mergers and acquisitions and joint ventures. Many of the transactions on which she advises involve an international perspective. Nicola works extensively with John Wilkinson advising clients in the life sciences sector. Before joining Bird & Bird, Nicola spent several years working as Legal Counsel for US multi-national, GE, and for Cable and Wireless advising on corporate matters and a broad range of commercial issues.

spacer
John Wilkinson
spacer
spacer
spacer
Nicola Maguire
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement